Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
Claims What is claimed is: 1. A compound 20 to 80 nucleobases in length targeted to a nucleic acid molecule encoding forkhead box O1A, wherein the compound is at least 70% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises the nucleobase sequence of SEQ ID NO: 172. 2. An antisense oligonucleotide 8 to 80 nucleobases in length targeted to the nucleic acid molecule of SEQ ID NO: 4 encoding forkhead box O1A, wherein the compound is at least 75% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises at least 8 consecutive nucleobases of SEQ ID NO: 172. 3. The compound of claim 1 which is an antisense oligonucleotide. 4. The compound of claim 3 wherein the antisense oligonucleotide comprises at least one modified intemucleoside linkage. 5. The compound of claim 4 wherein the modified intemucleoside linkage is a phosphorothioate linkage. 6. The compound of claim 3 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The compound of claim 3 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The compound of claim 3 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11 further comprising a colloidal dispersion system. 13. The composition of claim 11 wherein the compound is an antisense oligonucleotide. 14. A method of decreasing the expression of forkhead box O1A in cells or tissues comprising contacting the cells or tissues with a compound of claim 1 so that expression of forkhead box O1A is decreased. 15. The method of claim 14 wherein the tissues or cells is liver or fat tissue or cells. 16. A method of treating an animal having a disease or condition associated with forkhead box O1A comprising administering to the animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased. 17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder. 18. The method of claim 17 wherein the hyperproliferative disorder is cancer. 19. The method of claim 18 wherein the cancer is rhabdomyosarcoma. 20. The method of claim 16 wherein the disease or condition is diabetes. 21. The method of claim 20 wherein the diabetes is type 2. 22. A method of decreasing blood or plasma glucose in an animal comprising administering to the animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased. 23. A method of improving glucose tolerance in an animal comprising administering to the animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased. 24. A method of normalizing insulin levels in an animal comprising administering to said animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead O1A is decreased. 25. An antisense oligonucleotide 15 to 30 nucleobases in length comprising at least 8 consecutive nucleobases of SEQ ID NO: 172 wherein the oligonucleotide is at least 75% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A. 26. The antisense oligonucleotide of claim 25 wherein the oligonucleotide is at least 80% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A. 27. The antisense oligonucleotide of claim 25 wherein the oligonucleotide is at least 90% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A. 28. The antisense oligonucleotide of claim 25 wherein the oligonucleotide is at least 95% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A. 29. The antisense oligonucleotide of claim 25 wherein said oligonucleotide is 20 nucleobases in length. 30. A compound 20 nucleobases in length comprising the nucleobase sequence of SEQ ID NO: 172. 31. The compound of claim 30 further comprising at least one modified internucleoside linkage or at least one modified sugar moiety. 32. The compound of claim 30 further comprising at least one 2'-O-methoxyethyl sugar moiety. 33. The compound of claim 30 characterized by a ten deoxynucleotide gap flanked on its 5' and 3' ends with 5 2'-O-methoxyethyl nucleotides. 34. The compound of claim 33 further comprising phosphorothioate linkages for each internucleoside linkage. 35. The compound of claim 33 further comprising a 5-methylcytosine for each cytosine. 